Ellevest Inc. Sells 3,077 Shares of Sanofi (NASDAQ:SNY)

Ellevest Inc. reduced its position in Sanofi (NASDAQ:SNY) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,250 shares of the company’s stock after selling 3,077 shares during the quarter. Ellevest Inc.’s holdings in Sanofi were worth $736,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Arkadios Wealth Advisors boosted its stake in shares of Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after purchasing an additional 751 shares in the last quarter. Kentucky Trust Co acquired a new stake in shares of Sanofi in the 4th quarter worth $436,000. Park Avenue Securities LLC raised its position in shares of Sanofi by 14.3% in the 4th quarter. Park Avenue Securities LLC now owns 68,982 shares of the company’s stock valued at $3,327,000 after purchasing an additional 8,615 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Sanofi by 18.1% during the fourth quarter. Van ECK Associates Corp now owns 662,762 shares of the company’s stock worth $31,965,000 after buying an additional 101,726 shares during the period. Finally, Sound Income Strategies LLC increased its holdings in shares of Sanofi by 156,520.9% in the fourth quarter. Sound Income Strategies LLC now owns 67,347 shares of the company’s stock valued at $3,248,000 after purchasing an additional 67,304 shares during the period. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 target price on the stock. BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price target for the company. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Sanofi currently has a consensus rating of “Buy” and an average target price of $63.33.

Sanofi Stock Down 4.1 %

Sanofi stock opened at $49.98 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm has a market capitalization of $126.26 billion, a price-to-earnings ratio of 20.07, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The stock’s fifty day moving average is $54.22 and its two-hundred day moving average is $52.00.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company’s revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.78 EPS. Analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a $2.0369 dividend. This represents a yield of 3.1%. This is a boost from Sanofi’s previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi’s dividend payout ratio (DPR) is presently 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.